Research Paper Volume 12, Issue 2 pp 1285—1303

DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer

Figure 3. (A) For OS, Kaplan–Meier method revealed DNAH10 mutation (blue) and wild type (red) in the dataset of 101 patients with SCLC (reported by George et al); (B) For PFS, Kaplan–Meier method revealed DNAH10 mutations (blue) and wild type (red) in SCLC (NCT03162705). (C) For OS, Kaplan–Meier method showed DNAH10 mutations (red) and wild type (green) in the TCGA-LUAD dataset; (D) For OS, Kaplan–Meier method revealed DNAH10 mutations (red) and wild type (green) in the TCGA-LUSC dataset; SCLC: Small-cell lung cancer; TCGA: The Cancer Genome Atlas; WES: whole-exome sequencing; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; PFS: progression-free survival; OS: overall survival.